Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial in Japan of PLX PAD in patients with critical limb ischaemia.

Next Previous
Trial Profile

Phase II trial in Japan of PLX PAD in patients with critical limb ischaemia.

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 04 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emiplacel (Primary)
  • Indications Chronic limb-threatening ischemia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
    • 10 May 2016 According to a Pluristem media release, the company anticipates that data from this trial will lead to conditional marketing approval for PLX-PAD in the treatment of Critical Limb Ischemia in Japan.
    • 10 May 2016 According to Pluristem media release, Japan's Pharmaceuticals and Medical Devices Agency has cleared the protocol for this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top